BIOMAT Database Logo BIOMAT Database Logo

Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. 2000

H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Michigan Bone and Mineral Clinic, Detroit, Michigan 48236, USA.

The bisphosphonate alendronate and conjugated equine estrogens are both widely used for the treatment of postmenopausal osteoporosis. Acting by different mechanisms, these two agents decrease bone resorption and thereby increase or preserve bone mineral density (BMD). The comparative and combined effects of these medications have not been rigorously studied. This prospective, double blind, placebo-controlled, randomized clinical trial examined the effects of oral alendronate and conjugated estrogen, in combination and separately, on BMD, biochemical markers of bone turnover, safety, and tolerability in 425 hysterectomized postmenopausal women with low bone mass. In addition, bone biopsy with histomorphometry was performed in a subset of subjects. Treatment included placebo, alendronate (10 mg daily), conjugated equine estrogen (CEE; 0.625 mg daily), or alendronate (10 mg daily) plus CEE (0.625 mg daily) for 2 yr. All of the women received a supplement of 500 mg calcium daily. At 2 yr, placebo-treated patients showed a mean 0.6% loss in lumbar spine BMD, compared with mean increases in women receiving alendronate, CEE, and alendronate plus CEE of 6.0% (P < 0.001 vs. placebo), 6.0% (P < 0.001 vs. placebo), and 8.3% (P < 0.001 vs. placebo and CEE; P = 0.022 vs. alendronate), respectively. The corresponding changes in total proximal femur bone mineral density were +4.0%, +3.4%, +4.7%, and +0.3% for the alendronate, estrogen, alendronate plus estrogen, and placebo groups, respectively. Both alendronate and CEE significantly decreased biochemical markers of bone turnover, specifically urinary N-telopeptide of type I collagen and serum bone-specific alkaline phosphatase. The alendronate plus CEE combination produced slightly greater decreases in these markers than either treatment alone, but the mean absolute values remained within the normal premenopausal range. Alendronate, alone or in combination with CEE, was well tolerated. In the subset of patients who underwent bone biopsies, histomorphometry showed normal bone histology with the expected decrease in bone turnover, which was somewhat more pronounced in the combination group. Thus, alendronate and estrogen produced favorable effects on BMD. Combined use of alendronate and estrogen produced somewhat larger increases in BMD than either agent alone and was well tolerated.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001842 Bone and Bones A specialized CONNECTIVE TISSUE that is the main constituent of the SKELETON. The principal cellular component of bone is comprised of OSTEOBLASTS; OSTEOCYTES; and OSTEOCLASTS, while FIBRILLAR COLLAGENS and hydroxyapatite crystals form the BONE MATRIX. Bone Tissue,Bone and Bone,Bone,Bones,Bones and Bone,Bones and Bone Tissue,Bony Apophyses,Bony Apophysis,Condyle,Apophyses, Bony,Apophysis, Bony,Bone Tissues,Condyles,Tissue, Bone,Tissues, Bone
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004966 Estrogens, Conjugated (USP) A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate. Conjugated Equine Estrogen,Conjugated Estrogen,Estrogenic Substances, Conjugated,Progen,Carentil,Climarest,Climopax,Congest,Conjugated Equine Estrogens,Conjugated Estrogens,Dagynil,Estro-Feminal,Estrogenic Hormones, Conjugated,Estrogens, Conjugated,Femavit,Oestro-Feminal,Oestrofeminal,Prelestrin,Premarin,Presomen,Progens,Transannon,Conjugated Estrogenic Hormones,Conjugated Estrogenic Substances,Equine Estrogen, Conjugated,Equine Estrogens, Conjugated,Estro Feminal,Estrogen, Conjugated,Estrogen, Conjugated Equine,Oestro Feminal
D005260 Female Females
D006736 Horses Large, hoofed mammals of the family EQUIDAE. Horses are active day and night with most of the day spent seeking and consuming food. Feeding peaks occur in the early morning and late afternoon, and there are several daily periods of rest. Equus caballus,Equus przewalskii,Horse, Domestic,Domestic Horse,Domestic Horses,Horse,Horses, Domestic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
June 2005, Pharmacy world & science : PWS,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism.
February 2003, The Journal of clinical endocrinology and metabolism,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Romosozumab in postmenopausal women with low bone mineral density.
January 2014, The New England journal of medicine,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Denosumab in postmenopausal women with low bone mineral density.
February 2006, The New England journal of medicine,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Denosumab in postmenopausal women with low bone mineral density.
June 2006, The New England journal of medicine,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Denosumab in postmenopausal women with low bone mineral density.
June 2006, The New England journal of medicine,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Denosumab in postmenopausal women with low bone mineral density.
July 2006, Current oncology reports,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Denosumab in postmenopausal women with low bone mineral density.
April 2007, Current rheumatology reports,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
January 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,
H G Bone, and S L Greenspan, and C McKeever, and N Bell, and M Davidson, and R W Downs, and R Emkey, and P J Meunier, and S S Miller, and A L Mulloy, and R R Recker, and S R Weiss, and N Heyden, and T Musliner, and S Suryawanshi, and A J Yates, and A Lombardi
Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis.
January 2006, Advances in therapy,
Copied contents to your clipboard!